Rho guanine nucleotide exchange factor
From Proteopedia
(Difference between revisions)
| Line 8: | Line 8: | ||
== Disease == | == Disease == | ||
Increased GEF activity is involved in cancer cell proliferation by affecting Rho GTPases <ref>PMID:24037532</ref>. | Increased GEF activity is involved in cancer cell proliferation by affecting Rho GTPases <ref>PMID:24037532</ref>. | ||
| + | == 3D Structures of Rho guanine nucleotide exchange factor == | ||
| + | [[Rho guanine nucleotide exchange factor 3D structures]] | ||
</StructureSection> | </StructureSection> | ||
| Line 56: | Line 58: | ||
*Rho guanine nucleotide exchange factor 8 (PRONE8) | *Rho guanine nucleotide exchange factor 8 (PRONE8) | ||
| + | **[[3eo2]] – hGEF residues 161-373 <br /> | ||
| + | **[[4xh9]] – hGEF DH/PH domain + transforming protein RhoA <br /> | ||
**[[2ntx]] – AtGEF PRONE domain – ''Arabidopasis thaliana''<br /> | **[[2ntx]] – AtGEF PRONE domain – ''Arabidopasis thaliana''<br /> | ||
**[[2wbl]] – AtGEF PRONE domain + GTPase ROP7 <br /> | **[[2wbl]] – AtGEF PRONE domain + GTPase ROP7 <br /> | ||
**[[2nty]] – AtGEF PRONE domain + GTPase ROP4 + GDP <br /> | **[[2nty]] – AtGEF PRONE domain + GTPase ROP4 + GDP <br /> | ||
| - | **[[3eo2]] – hGEF residues 161-373 <br /> | ||
| - | **[[4xh9]] – hGEF DH/PH domain + transforming protein RhoA <br /> | ||
*Rho guanine nucleotide exchange factor 9 (collybistin) | *Rho guanine nucleotide exchange factor 9 (collybistin) | ||
Revision as of 10:34, 15 December 2019
| |||||||||||
3D Structures of Rho guanine nucleotide exchange factor
Updated on 15-December-2019
References
- ↑ Cherfils J, Zeghouf M. Regulation of small GTPases by GEFs, GAPs, and GDIs. Physiol Rev. 2013 Jan;93(1):269-309. doi: 10.1152/physrev.00003.2012. PMID:23303910 doi:http://dx.doi.org/10.1152/physrev.00003.2012
- ↑ Cook DR, Rossman KL, Der CJ. Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease. Oncogene. 2014 Jul 31;33(31):4021-35. doi: 10.1038/onc.2013.362. Epub 2013 Sep, 16. PMID:24037532 doi:http://dx.doi.org/10.1038/onc.2013.362
